Correspondence

**SAPHO syndrome in pediatric patients with inflammatory bowel disease treated with infliximab**

Dear Editor,

SAPHO syndrome is a rare disease with bone involvement (aseptic osteitis) and skin manifestations (palm-plantar pustulosis, acne or pustular psoriasis). Due to its subtle clinical presentation, it is often misdiagnosed and unrecognized. The association between SAPHO and inflammatory bowel disease (IBD) has been reported since 1992, with a few pediatric cases described so far [1]. Here we describe two cases of SAPHO syndrome, which occurred in two adolescent girls with Crohn’s disease (CD) and Ulcerative colitis (UC), respectively. In contrast to previous reports our patients developed the clinical features of the syndrome during treatment with Infliximab (IFX), despite remission of the underlying IBD.

A Caucasian girl was diagnosed with CD at the age of 7 years due to a complex perianal fistulizing disease. An MRI of the pelvis revealed an inter-sphincter fistula and two peri-anal abscesses. Endoscopic examination and histological findings were consistent with CD. According to current recommendations [2], IFX was started after drainage and fistulotomy, with attainment of complete remission. After 2 years of maintenance regimen with infusions every 8 weeks, endoscopy revealed mucosal healing. Infliximab was then discontinued and 6-Mercaptopurine was started at a dosage of 1.5 mg/kg/day. However, after 15 months, IFX was resumed due to CD luminal relapse. With scheduled IFX therapy, she again achieved clinical remission and such treatment was continued for 3 years without need of dose adjustment and with normal growth. At the age of 14, endoscopic examination showed deep remission with mucosal healing. Serum levels of IFX were in the therapeutic range (14.736 mcg/ml) and anti-IFX antibodies were absent. Fecal calprotectin levels were persistently low at serial measurement. Three months later, 7 weeks after her last IFX infusion, she developed a palm-plantar vesiculopustular rash (Fig. 1a) initially diagnosed as Coxsackie infection. After a few days she developed low-grade fever and marked fatigue. She was admitted to a peripheral hospital where an inter-Tumor Necrosis Factor α (anti-TNFα) inducing cutaneous reaction was suspected. Despite local treatment with tazarotene and IFX discontinuation, systemic symptoms did not subside, and additional cutaneous lesions appeared at the trunk and lower extremities. Moreover, the patient started to complain of severe bone pain in multiple sites (jaw, left scapula, lumbar spine, right knees). Thus, she was transferred to our hospital. An infectious disease work-up, including mycobacteria, was negative. Dermatologic findings (Fig. 1a-c) were congruent with anti-TNFα induced reaction, given the concomitance of psoriasiform ecema with secondary alopecia and palm-plantar pustulosis. However, whole-body MRI showed osteitis at clavicle, multiple costae, vertebral bodies, distal femur and proximal tibia bilaterally (Fig. 2a-b). Bone biopsy confirmed the chronic aseptic inflammatory process, ruling out malignancy or infectious disease. According to the proposed Kahn criteria [3], a diagnosis of active SAPHO syndrome was made. In consideration of the marked involvement of vertebral bodies, treatment with Pamidronate (1 mg/kg/day for 3 days) was initiated. Pamidronate was discontinued after the first infusion because of a sharp rise of liver enzymes compatible with drug-induced liver injury. Since Crohn’s disease was still in remission (fecal calprotectin level 8 mcg/g; normal intestinal ultrasound) despite active SAPHO syndrome, a switch to Adalimumab (ADA) was attempted at a dosage used for rheumatic conditions (24 mg/m² every two weeks) in combination with methotrexate (15 mg/m² weekly subcutaneously). Both cutaneous and osteoarticular manifestations dramatically improved with this treatment and she maintains clinical remission and negative inflammation markers at the 12-months follow-up. Total Body MRI showed a marked decrease of bone inflammatory lesions (Fig. 2c).

The second case was a Caucasian girl, diagnosed with UC at 8 years of age. Past medical history was significant only for mild psoriasis, treated with topical medications. Because of pancolitis at disease onset, induction treatment with corticosteroid was successfully adopted and then followed by maintenance treatment with 5-aminosalicylic acid (5-ASA). However, 5-ASA was discontinued after six months due to intolerance and the girl maintained spontaneous remission without therapy for the following two years. At the age of 11, the girl was admitted to hospital for an acute severe attack of UC, unresponsive to corticosteroid, and IFX was started, according to current guidelines [4]. Following IFX therapy, she achieved clinical remission with low fecal calprotectin; thus, azathioprine was added as maintenance treatment. After two months thiopurine-induced leukopenia led to treatment discontinuation and IFX monotherapy was continued. Serum levels of IFX and anti-IFX antibodies were not available. Endoscopic evaluation after eight months of IFX reported only mild inflammation at cecum and fecal calprotectin was 25 mcg/g, so dose adjustment was not required.

At the age of 12 years (after 16 months of IFX treatment), the patient presented with micro-pustular rash at the trunk with onset 6 weeks after her last IFX infusion: initially a diagnosis of folliculitis was made, and topical erythromycin was started, with only partial response. During the following two weeks, the patient experienced severe bone pain at the spine and hip with antalgic scoliosis. So, she was admitted to our hospital, where a new dermatologic examination documented sterile pustulosis on soles and erythematous-squamous plaques on the scalp and on the trunk. IFX treatment was discontinued and topical therapy with steroid and emollients was started.

A whole-body MRI showed osteitis at several vertebral bodies, sacro-iliac joints, clavicle and sternum. Therefore, she was diagnosed with SAPHO syndrome and treatment with Pamidronate (1 mg/kg/day for 3 days) was started. Due to persistence of bone

1590-8658/© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
pain after treatment, she received ADA (24 mg/mq² every two
weeks) with subsequent improvement of both cutaneous and
skeletal symptoms and normalization of inflammatory markers at
a 4-months follow-up.

The acronym SAPHO stands for synovitis, acne, pustulosis,
hyperostosis and ostitis, thus explaining the prominent features
of the disease. Nowadays, this condition is considered part of the
spectrum of chronic non-infectious osteomyelitis (CNO), a group
of rare multifactorial autoinflammatory disease of the bone char-
terized by aseptic chronic bone inflammation [3]. The association
between SAPHO and IBD have been reported in literature, with an
estimated prevalence of around 0.2% in a cohort of IBD patients
and as high as 5% in patients with a primary diagnosis of SAPHO
[1]. An underestimation of the exact prevalence of SAPHO among
IBD patients might be due to clinical similarities with some extra-
intestinal manifestations of IBD and drug-related side effects, such
as palmoplantar pustulosis. Palmoplantar psoriasis is indeed fre-
quently associated with anti-TNFα use in IBD patients and it might
pose a diagnostic challenge [3].

In SAPHO syndrome anti-TNFα have proven to be effective [6],
thus suggesting a crucial role for TNF-α as a mediator in SAPHO
pathogenesis. However, our patients developed SAPHO syndrome
while under anti TNFα treatment. In addition, in both patients the
underlying IBD was in remission and thus this was in contrasts with
the reported association between active bowel inflammation and
clinical manifestation of SAPHO syndrome [1]. So far, only two cases
of SAPHO have been reported during treatment with anti-TNFα:
two adult patients with IBD received a diagnosis of SAPHO shortly
after starting treatment with IFX and ADA, respectively [7,8]. In the
latter case, the authors suggested a causal relationship between
adalimumab treatment and SAPHO manifestation. In our opinion,
the potential triggering role of IFX in these cases is controversial.
On one hand, along with palm-plantar pustulosis or pustular psoriasis,
two prominent features of SAPHO, the patients presented
with xerosis and psoriasiform eczema, which have been recorded as
common cutaneous adverse events in patients treated with IFX [9].
On the other hand, the clinical features of SAPHO initially worsened
despite IFX discontinuation, while improving when they had been
given a second anti-TNFα treatment (adalimumab). Moreover, the clinical evolution of our patient is in contrast with the high percentage of recurrence or persistence of the rash in patients with anti-TNFα induced psoriasis and treated with a second anti-TNFα [5]. Indeed, cutaneous adverse events under anti-TNFα are known to be class-specific, since they are related to the inhibition of the physiological function of TNFα in the skin [10]. Therefore, these clues lead us to consider the possibility of SAPHO syndrome onset as a de novo event not related to the concomitant treatment with IFX.

Because of the rarity of the association, treatment of patients with SAPHO and IBD is not standardized. Due to vertebral spine involvement, we preferred bisphosphonate as first line therapy for our patients, in line with current evidence from SAPHO and CNO [3]. Adalimumab was then administered because of reported good response of SAPHO to this agent [3]. However, a low rheumatologic dosage was chosen, considering that IBD was in remission in both patients; in addition, other immunomodulatory agents were given in combination with ADA. Methotrexate was added in the first case in which pamidronate was discontinued due to an adverse effect; in the second patient a course of pamidronate was completed before treatment with ADA.

Hence, SAPHO syndrome should be excluded in IBD patients complaining of skin and osteo-articular symptoms, irrespective of the resolution of intestinal inflammation and simultaneous biologic treatment. Further cases are necessary to elucidate the mechanisms underlying SAPHO during TNF-inhibition and to determine whether a causal link might exist.

Conflict of interest
None declared.

Acknowledgment

We thanks Roberto Maglie, MD, to have contributed to clinical data collection and review of paradoxical skin reactions of anti-TNF.

References


Allogeneic mesenchymal stromal cells for refractory luminal Crohn’s disease: A phase I–II study

Dear Editor,

Crohn’s disease (CD) is a complex chronic relapsing disease involving abnormal systemic and mucosal immune responses against intraluminal antigens, favoured by microbial factors and alteration of the mucosal barrier. A key role in its pathogenesis is played by the imbalance between proinflammatory T helper (Th)1/Th17 cells and regulatory T lymphocytes (Treg), resulting in activation of macrophages and B cells, and recruitment of circulating leukocytes into the gut. Mesenchymal stromal cells (MSCs) exert potent immunomodulatory effects and exhibit interesting properties for tissue repair [1]. Local and intravenous injections of MSCs have demonstrated their safety in fistulising and luminal CD [1]. The efficacy of locally administered MSCs in perianal fistulas associated with CD has been shown in two randomised controlled trials [2,3], but systemic infusions of MSCs still need to prove their efficacy in luminal CD. Moreover, the mechanisms of action of MSCs in CD are not fully understood, and the best treatment parameters still need to be determined.

In this pilot phase I–II open-label trial, we aimed to further assess safety and efficacy of intravenous injections of allogeneic bone marrow (BM)-MSCs in severe refractory CD and to characterise blood immune cells during therapy in order to better understand the mechanisms of action of MSCs in CD.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, was approved by the ethics committees of the University Hospital of Liége and the Belgian Federal Agency for Medicines and Health Product, and registered at ClinicalTrials.gov (NCT01540292). Signed informed consent was obtained from participating subjects. Inclusion criteria were age between 18 and 75 years, CD according to Lennard-Jones criteria, clinically and biologically active disease with